2019

• Nelson, A., Mann, M. and Staffurth, J. 2019. Methods of assessing late radiotherapy effects on bowel function. Current Opinion in Supportive and Palliative Care 13(2), pp. 134-141. (10.1097/SPC.0000000000000422)
• Hargreaves, S.et al. 2019. Interim 18F-FDG positron emission tomography/computed tomography during chemoradiotherapy in the management of cancer patients: a response [Letter]. Clinical Oncology (10.1016/j.clon.2019.05.005)
• Wheeler, P. A.et al. 2019. Utilisation of Pareto navigation techniques to calibrate a fully automated radiotherapy treatment planning solution. Physics and Imaging in Radiation Oncology 10, pp. 41-48. (10.1016/j.phro.2019.04.005)
• Parkinson, C.et al. 2019. Machine-learned target volume delineation of 18F-FDG PET images after one cycle of induction chemotherapy. Physica Medica, European Journal of Medical Physics 61, pp. 85-93. (10.1016/j.ejmp.2019.04.020)
• Jadon, R.et al. 2019. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy. Radiation Oncology 14(1), pp. -., article number: 57. (10.1186/s13014-019-1262-8)
• Wheeler, P.et al. 2019. OC-0183 Multi-institutional evaluation of a Pareto navigation guided automated planning solution. Radiotherapy and Oncology 133, pp. S92. (10.1016/S0167-8140(19)30603-6)
• Whybra, P.et al. 2019. PO-0963 A novel normalisation technique for voxel size dependent radiomic features in oesophageal cancer. Radiotherapy and Oncology 133, pp. S523-S524. (10.1016/S0167-8140(19)31383-0)
• Evans, E.et al. 2019. EP-1666 ARENA: Improving training in target volume delineation for radiotherapy. Radiotherapy and Oncology 133, pp. S896-S897. (10.1016/S0167-8140(19)32086-9)
• Piazzese, C.et al. 2019. PO-0964 Stability and prognostic significance of CT radiomic features from oesophageal cancer patients. Radiotherapy and Oncology 133, pp. S524. (10.1016/S0167-8140(19)31384-2)
• Foley, K.et al. 2019. External validation of a prognostic model incorporating quantitative PET image features in esophageal cancer. Radiotherapy and Oncology 133, pp. 205-212. (10.1016/j.radonc.2018.10.033)
• Dearnaley, D.et al. 2019. Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL). International Journal of Radiation Oncology - Biology - Physics 103(3), pp. 605-617. (10.1016/j.ijrobp.2018.10.003)
• Richards, R.et al. 2019. The preferences of patients with cancer regarding an app to help them to meet their illness-related information needs: a qualitative interview study. European Journal of Hospital Pharmacy

2018

• Parkinson, C.et al. 2018. Dependency of patient risk stratification on PET target volume definition in oesophageal cancer. Presented at: ESTRO, Barcelona, Spain, 20-24 April 2018.
• Richards, B.et al. 2018. The use of mobile devices to help patients with cancer to meet their illness-related information needs in non-inpatient settings: a systematic review. JMIR mHealth and uHealth 6(2), article number: e10026. (10.2196/10026)
• Payne, H.et al. 2018. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice. International Journal of Clinical Practice, article number: e13292. (10.1111/ijcp.13292)
• Parkinson, C.et al. 2018. ATLAAS - Investigation into the incorporation of morphological data on automated segmentation. Presented at: EANM Congress 2018: European Association of Nuclear Medicine., Dusseldorf, Germany, 12-18 October 2018.
• Parkinson, C.et al. 2018. Target volume delineation of FDG PET images post one cycle of induction chemotherapy in oropharyngeal cancer using advanced automated segmentation methods. Presented at: ESTRO 37, Barcelona, 20-24 April 2018.
• Parkinson, C.et al. 2018. Evaluation of prognostic models developed using standardised image features from different PET automated segmentation methods. EJNMMI Research 8, article number: 29. (10.1186/s13550-018-0379-3)
• Donovan, J. L.et al. 2018. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology 96, pp. 35-46. (10.1016/j.jclinepi.2017.12.019)
• Parkinson, C.et al. 2018. Dependency of patient risk stratification on PET target volume definition in Oesophageal cancer. Radiotherapy and Oncology 127, pp. S503-S504. (10.1016/S0167-8140(18)31241-6)
• Parkinson, C.et al. 2018. Target volume delineation of PET post one cycle of induction chemotherapy in oropharyngeal cancer. Radiotherapy and Oncology 127(Suppl), pp. S634-S635. (10.1016/S0167-8140(18)31436-1)
• Murray, J.et al. 2018. Erectile potency and radiation dose to the penile bulb dose constraints derived from the CHHiP randomised prostate radiotherapy trial. European Urology
• Whybra, P.et al. 2018. Effect of interpolation on 3D texture analysis of PET imaging in oesophageal cancer. Radiotherapy and Oncology 127, pp. S1164-S1165. (10.1016/S0167-8140(18)32426-5)

2017

• Wills, L.et al. 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12(1), article number: 179. (10.1186/s13014-017-0916-7)
• Hurt, C. N.et al. 2017. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. British Journal of Cancer 116(10), pp. 1264-1270. (10.1038/bjc.2017.95)
• Crosby, T.et al. 2017. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/? cetuximab in oesophageal cancer. British Journal of Cancer 116(6), pp. 709-716. (10.1038/bjc.2017.21)

2016

• Gnanapragasam, V.et al. 2016. Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup. Journal of Clinical Urology 9(6), pp. 369-379. (10.1177/2051415816651362)
• Johnston, T. J.et al. 2016. Mortality among men with advanced prostate cancer excluded from the ProtecT trial. European Urology 71(3), pp. 381-388. (10.1016/j.eururo.2016.09.040)
• Taylor, S.et al. 2016. The three-item ALERT-B questionnaire provides a validated screening tool to detect chronic gastrointestinal symptoms after pelvic radiotherapy in cancer survivors. Clinical Oncology 28(10), pp. e139-e147. (10.1016/j.clon.2016.06.004)
• Taylor, S.et al. 2016. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. British Medical Journal Open 6(10), article number: e011773. (10.1136/bmjopen-2016-011773)
• Tanguay, J. S.et al. 2016. High risk of neutropenia for hormone-naive prostate cancer patients receiving STAMPEDE-style upfront Docetaxel chemotherapy in usual clinical practice. Clinical Oncology 28(9), pp. 611-611. (10.1016/j.clon.2016.03.006)
• Fokas, E.et al. 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120(2), pp. 212-216. (10.1016/j.radonc.2016.07.002)
• Dearnaley, D.et al. 2016. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncology 17(8), pp. 1047-1060. (10.1016/S1470-2045(16)30102-4)
• Andronis, L.et al. 2016. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International 119(4), pp. 522-529. (10.1111/bju.13549)
• James, N.et al. 2016. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment 20(53) (10.3310/hta20530)
• Fokas, E.et al. 2016. P-222 Analysis of tumour contours and radiotherapy planning of "on-trial" patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of "on-trial" radiotherapy?. Annals of Oncology 27(suppl), pp. ii64.3-ii65.. (10.1093/annonc/mdw199.214)
• Sharma, R. A.et al. 2016. Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology 13, pp. 627-642. (10.1038/nrclinonc.2016.79)
• James, N. D.et al. 2016. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both. JAMA Oncology 2(4), pp. 493-499. (10.1001/jamaoncol.2015.5570)
• Carrington, R.et al. 2016. The influence of radiotherapy treatment method on dose distribution and its relation to patient outcome in the SCOPE 1 oesophageal cancer trial using Type B algorithms. BMC Medical Physics 42(6), pp. 3703-3703. (10.1186/s13014-016-0594-x)
• Carrington, R.et al. 2016. The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial. Radiation Oncology 11(19), pp. 1-8. (10.1186/s13014-016-0594-x)
• Abraham, J. and Staffurth, J. N. 2016. Hormonal therapy for cancer. Medicine 44(1), pp. 30-33. (10.1016/j.mpmed.2015.10.014)
• Taylor, S. E.et al. 2016. Late effects of pelvic radiation treatment (EAGLE study) [Abstract]. Journal of Clinical Oncology 34(3), pp. 159. (10.1200/jco.2016.34.3_suppl.159)
• Gwynne, S.et al. 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89(1064), article number: 20160020. (10.1259/bjr.20160020)

2015

• Fokas, E.et al. 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117(3), pp. 432-437. (10.1016/j.radonc.2015.08.026)
• Carrington, R.et al. 2015. The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. Radiation Oncology 10, article number: 236. (10.1186/s13014-015-0537-y)
• Hurt, C. N.et al. 2015. Health-related quality of life in SCALOP, a randomized Phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics 93(4), pp. 810-818.
• Hurt, C. N.et al. 2015. Health related quality of life in SCALOP, a randomized phase II trial comparing chemoradiotherapy regimens in locally advanced pancreatic cancer (LAPC). International Journal of Radiation Oncology*Biology*Physics 93(4), pp. 810-818. (10.1016/j.ijrobp.2015.08.026)
• Rees, J.et al. 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113(4), pp. 603-610. (10.1038/bjc.2015.258)
• Harris, V. A.et al. 2015. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. International Journal of Radiation Oncology*Biology*Physics 92(4), pp. 874-883. (10.1016/j.ijrobp.2015.03.021)
• Carrington, R.et al. 2015. A radiobiological investigation of dose escalation in lower oesophageal tumours with a focus on gastric toxicity. Medical Physics 42(6), pp. 3346-3347. (10.1118/1.4924430)
• Salimu, J.et al. 2015. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunology Research 3(6), pp. 678-688. (10.1158/2326-6066.CIR-14-0079)

2014

• Adamson, D.et al. 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15, article number: 402. (10.1186/1745-6215-15-402)
• Spary, L. K.et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192(7), pp. 3101-3110. (10.4049/jimmunol.1302736)
• Jadon, R.et al. 2014. A systematic review of organ motion and image-guided strategies in external beam radiotherapy for cervical cancer. Clinical Oncology 26(4), pp. 185-196. (10.1016/j.clon.2013.11.031)
• Voskoboynik, M.et al. 2014. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy 14(11), pp. 1253-1256. (10.1586/14737140.2014.971112)

2013

• Nixon, L. S.et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87(2), pp. S306. (10.1016/j.ijrobp.2013.06.804)
• Thomas, B. M.et al. 2013. Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. Medical Oncology 30(4), article number: 719. (10.1007/s12032-013-0719-0)
• Crosby, T. D. L.et al. 2013. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology 14(7), pp. 627-637. (10.1016/S1470-2045(13)70136-0)
• Mukherjee, S.et al. 2013. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. The Lancet Oncology 14(4), pp. 317-326. (10.1016/S1470-2045(13)70021-4)
• Crosby, T.et al. 2013. SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. American Journal of Clinical Oncology 31(Supp 4), article number: LBA3. (10.1200/jco.2013.31.4_suppl.lba3)
• Mukherjee, S.et al. 2013. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by genicitabine (G) or capecitabine (Cap) based chentoradialion (CRT) in locally advanced pancreatic cancer (LANPC).. American Journal of Clinical Oncology 31(Supp 4)
• Mukherjee, S.et al. 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31(4), article number: 230.

2012

• Burnet, N. G.et al. 2012. Methodological considerations in the evaluation of radiotherapy technologies [Editorial]. Clinical Oncology 24(10), pp. 707-709. (10.1016/j.clon.2012.06.003)
• Hummel, S. R.et al. 2012. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clinical Oncology 24(10), pp. e159-e167. (10.1016/j.clon.2012.09.003)
• Gwynne, S. H.et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84(4), pp. 1037-1042. (10.1016/j.ijrobp.2012.01.094)
• Mayles, W. P. M.et al. 2012. Progress with intensity-modulated radiotherapy implementation in the UK. Clinical Oncology 24(8), pp. 543-544. (10.1016/j.clon.2012.06.005)
• Fizazi, K.et al. 2012. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology 13(10), pp. 983-992. (10.1016/S1470-2045(12)70379-0)
• Mackay, R. I.et al. 2012. Radiotherapy physics research in the UK: challenges and proposed solutions. British Journal of Radiology 85(1018), pp. 1354-1362. (10.1259/bjr/61530686)
• Spezi, E.et al. 2012. Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy. International Journal of Radiation Oncology*Biology*Physics 83(1), pp. 419-426. (10.1016/j.ijrobp.2011.06.1972)
• Nilsson, S.et al. 2012. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. European Journal of Cancer 48(5), pp. 678-686. (10.1016/j.ejca.2011.12.023)
• Dearnaley, D.et al. 2012. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology 13(1), pp. 43-54. (10.1016/S1470-2045(11)70293-5)
• Gwynne, S. H.et al. 2012. Image-guided Radiotherapy for Rectal Cancer - A Systematic Review. Clinical Oncology 24(4), pp. 250-260. (10.1016/j.clon.2011.07.012)
• Gwynne, S. H.et al. 2012. Imaging for Target Volume Delineation in Rectal Cancer Radiotherapy - A Systematic Review. Clinical Oncology 24(1), pp. 52-63. (10.1016/j.clon.2011.10.001)

2011

• Gwynne, S.et al. 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81(2), pp. S67-S68. (10.1016/j.ijrobp.2011.06.135)
• de Bono, J. S.et al. 2011. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364(21), pp. 1995-2005. (10.1056/NEJMoa1014618)
• Gwynne, S.et al. 2011. Imaging for rectal cancer radiotherapy - a systematic review. Clinical Oncology 23(3), pp. S37-S37.

2010

• Tabi, Z.et al. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185(2), pp. 1330-1339. (10.4049/jimmunol.1000488)
• Welton, J. L.et al. 2010. Proteomics analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9(6), pp. 1324-1338. (10.1074/mcp.M000063-MCP201)
• Mukherjee, S.et al. 2010. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. American Journal of Clinical Oncology 28
• Guerrero Urbano, T.et al. 2010. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clinical Oncology 22(3), pp. 236-244. (10.1016/j.clon.2010.01.005)
• Routsis, D.et al. 2010. Education and training for intensity-modulated radiotherapy in the UK. Clinical Oncology 22(8), pp. 675-680. (10.1016/j.clon.2010.06.012)
• Staffurth, J. N. 2010. A review of the clinical evidence for intensity-modulated radiotherapy. Clinical Oncology 22(8), pp. 643-657. (10.1016/j.clon.2010.06.013)
• Williams, M. V.et al. 2010. The implementation of intensity-modulated radiotherapy in the UK. Clinical Oncology 22(8), pp. 623-628. (10.1016/j.clon.2010.06.015)
• Mackay, R. I.et al. 2010. UK guidelines for the safe delivery of intensity-modulated radiotherapy.. Clinical Oncology 22(8), pp. 629-635.
• Button, M. R. and Staffurth, J. N. 2010. Clinical Application of Image-guided Radiotherapy in Bladder and Prostate Cancer. Clinical Oncology 22(8), pp. 698-706. (10.1016/j.clon.2010.06.020)

2009

• Jones, C. E.et al. 2009. The development and introduction of a written post-radiotherapy information leaflet for prostate cancer patients [Abstract]. Clinical Oncology 21(3), pp. 270. (10.1016/j.clon.2009.01.001)
• Nixon, L. S.et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21(3), pp. 255-255. (10.1016/j.clon.2009.01.001,)
• Shelley, M. D.et al. 2009. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treatment Reviews 35(1), pp. 9-17. (10.1016/j.ctrv.2008.08.002)
• Mitchell, P. J.et al. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7(4), pp. n/a. (10.1186/1479-5876-7-4)
• Gwynne, S.et al. 2009. Respiratory movement of upper abdominal organs and its effect on radiotherapy planning in pancreatic cancer1. Clinical Oncology 21(9), pp. 713-719. (10.1016/j.clon.2009.07.015)
• Shelley, M. D.et al. 2009. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treatment Reviews 35(7), pp. 540-546. (10.1016/j.ctrv.2009.05.001)
• Wills, L.et al. 2009. The effect of planning algorithms in oesophageal radiotherapy in the context of the SCOPE 1 trial. Radiotherapy and Oncology 93(3), pp. 462-467. (10.1016/j.radonc.2009.08.036)
• Sutcliffe, P.et al. 2009. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technology Assessment 13(5), pp. 1-242. (10.3310/hta13050)

2008

• Hudson, E.et al. 2008. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies. Clinical Oncology 20(5), pp. 353-357. (10.1016/j.clon.2008.02.008)
• Abraham, J. and Staffurth, J. N. 2008. Hormonal therapy for cancer. Medicine 36(1), pp. 29-32. (10.1016/j.mpmed.2007.10.010)
• Abraham, J. and Staffurth, J. N. 2008. Hormones in cancer. In: Hanna, C. L., Crosby, T. and Macbeth, F. R. eds. Practical clinical oncology.. Cambridge: Cambridge University Press, pp. 23-38.
• Barber, J. and Staffurth, J. N. 2008. Prostate. In: Hanna, C. L., Crosby, T. and Macbeth, F. R. eds. Practical clinical oncology.. Cambridge: Cambridge University Press, pp. 231-239.
• Barber, J. and Staffurth, J. N. 2008. Testis. In: Hanna, C. L., Crosby, T. and Macbeth, F. R. eds. Practical clinical oncology.. Cambridge: Cambridge University Press, pp. 240-251.
• Staffurth, J. N. and Mason, M. D. 2008. Radiotherapy for early prostate cancer. In: Kirk, D. ed. International handbook of prostate cancer. 3rd ed.. Hampshire: Euromed Communications Limited, pp. 161-182.

2007

• Harnden, P.et al. 2007. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. The Lancet Oncology 8(5), pp. 411-419. (10.1016/S1470-2045(07)70136-5)